Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18760683 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL25095343 | 0.86 | ALDH1A1 (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL18748725 | 0.86 | ALDH1A1 (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL1939983 | 0.86 | KMT2A (0.48) | ALDH1A1KMT2ALMNAMEN1POLB | |
| SCHEMBL24333929 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KMT2ALMNAMEN1GAA | |
| SCHEMBL16349315 | 0.85 | HSD11B1 (0.47) | LMNA | |
| SCHEMBL14578756 | 0.85 | ALDH1A1 (0.58) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL4067415 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL3298234 | 0.82 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL114044 | 0.82 | ALDH1A1 (0.57) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ALDH1A1 72/4885CYP3A4 209/4885CYP2C9 131/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ALDH1A1 72/4885CYP3A4 209/4885CYP2C9 131/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | ALDH1A1 3634/4885CYP3A4 628/4885CYP2C9 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.